Biotech investors sound alarm on Senate drug-pricing bill By Susan Ferrechio - The Washington Times Shares
Biden stumps for big-spending agenda as a way to alleviate rising costs By Tom Howell Jr. - The Washington Times Shares
A stronger, more sustainable Medicare By Meena Seshamani, MD, PhD Director of Center for Medicare Shares
Activists call for adding new Alzheimer’s drug to Medicare coverage By Sean Salai - The Washington Times Shares
Biden calls on Democrats to pass drug negotiation, extend Obamacare subsidies By Tom Howell Jr. - The Washington Times Shares
Biden administration says Medicare enrollees can get free COVID tests by early spring By Tom Howell Jr. - The Washington Times Shares
$56K Alzheimer’s drug avoiding Biden’s cost curbs, for now By Ricardo Alonso-Zaldivar - Associated Press Shares
Sanders to Biden: Cut back looming Medicare premium hike By Ricardo Alonso-Zaldivar - Associated Press Shares
Alzheimer’s drug cited as Medicare premium jumps by $21.60 By Ricardo Alonso-Zaldivar - Associated Press Shares
‘Still being negotiated’: Progressives’ moves threaten to sink Biden’s framework bill By Valerie Richardson and Haris Alic - The Washington Times Shares
Far-left fears Democratic leaders’ drug-pricing compromise is a ‘sham’ to benefit Big Pharma By Kery Murakami - The Washington Times Shares
In a party of big spenders, Manchin’s $1.5 trillion limit is a lowball bid By Seth McLaughlin - The Washington Times Shares
Maryland residents eligible for free medical equipment By BETHANY PROBST Bethany Probst - Associated Press Shares
COVID-19 pandemic eats into Social Security’s solvency By Stephen Dinan - The Washington Times Shares